Journal of Endocrinological Investigation最新文献

{"title":"Process to radioactive iodine treatment for Graves' hyperthyroidism: condemned or absolved?","authors":"Luigi Bartalena, Daniela Gallo, George J Kahaly, Eliana Piantanida, Maria Laura Tanda","doi":"10.1007/s40618-025-02653-x","DOIUrl":"10.1007/s40618-025-02653-x","url":null,"abstract":"<p><strong>Background: </strong>Radioactive iodine (RAI) is an effective treatment for Graves' disease, as it eradicates hyperthyroidism in > 90% of cases after a single dose. It causes lifelong hypothyroidism. Its popularity has declined in the last 15 years, due to several reasons, including the desire to avoid permanent hypothyroidism and preserve the thyroid, the fear to increase all-cause mortality, cardiovascular/cerebrovascular mortality and major cardiovascular events (MACE), the concern about radiation-related (thyroidal and nonthyroidal) cancer or occurrence/progression of Graves' orbitopathy (GO), and pregnancy planning in the near future.</p><p><strong>Design: </strong>Narrative review.</p><p><strong>Results: </strong>Hyperthyroidism due to Graves' disease is associated with an increased risk of all-cause and cardiovascular/cerebrovascular mortality, MACE, cancer, occurrence/progression of GO, gonadal dysfunction in both sexes, impaired health-related quality of life (HR-QoL). RAI does not increase all-cause mortality, cardiovascular mortality, MACE, cancer, and may rather reduce them if treatment promptly results in hypothyroidism. RAI bears a small risk of de novo occurrence or progression of mild GO, preventable by steroid prophylaxis. It may be used also in moderate-to-severe and active GO, if the latter is concomitantly treated with high-dose immunosuppression. RAI neither permanently impairs gonadal function or fertility nor is associated with abnormalities in the offspring. Recent evidence on HR-QoL after RAI is reassuring.</p><p><strong>Conclusions: </strong>RAI is not only an effective treatment for Graves' hyperthyroidism, but is also safe. Its declining reputation should be rehabilitated. A balanced and unbiased presentation of its advantages and disadvantages by the physician to the patient is warranted.</p>","PeriodicalId":48802,"journal":{"name":"Journal of Endocrinological Investigation","volume":" ","pages":"1927-1950"},"PeriodicalIF":3.5,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144790480","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of sodium-glucose cotransporter 2 inhibitors on cardiomyopathy: a meta-analysis.","authors":"Bo Xu, Tianqiao Zhang, Jiecan Zhou","doi":"10.1007/s40618-025-02625-1","DOIUrl":"10.1007/s40618-025-02625-1","url":null,"abstract":"<p><strong>Background: </strong>Cardiomyopathies can present at any age and affect individuals and families across the entire life course. Clinical effects of sodium-glucose cotransporter 2 (SGLT2) inhibitors on cardiomyopathy have not yet been fully elucidated.</p><p><strong>Objective: </strong>The primary objective of this study was to investigate whether SGLT2 inhibitors have an effect on cardiomyopathy compared to placebo.</p><p><strong>Methods: </strong>We systematically searched for randomized double-blind placebo-controlled trials on PubMed, Web of Science, EU Clinical Trials Register, and ClinicalTrials.gov. We used the Mantel-Haenszel statistical method, fixed-effects model and risk ratio (RR) with 95% confidence intervals (CI) to analyze binary data.</p><p><strong>Results: </strong>A total of 19 studies were included, covering 97,035 participants. Compared to placebo, SGLT2 inhibitors were associated with a reduced risk of cardiomyopathy (RR 0.72; 95% CI 0.56-0.92; P < 0.01; high certainty of evidence), with non-significant heterogeneity (P_{heterogeneity}=0.81; I² = 0%), especially observed in the empagliflozin subgroup (RR 0.66; 95% CI 0.46-0.94; P = 0.02), chronic kidney disease (RR 0.67; 95% CI 0.47-0.97; P = 0.03) population and heart failure (RR 0.46; 95% CI 0.23-0.91; P = 0.03) population. However, in type 2 diabetes mellitus population, the effect of SGLT2 inhibitors on cardiomyopathy incidence was less clear (RR 0.76; 95% CI 0.51-1.12; P = 0.17; moderate certainty of evidence). Additionally, SGLT2 inhibitors were associated with a reduced risk of primary cardiomyopathy (RR 0.43; 95% CI 0.21-0.87; P = 0.02) and slightly decreased the incidence of secondary cardiomyopathy compared to placebo (RR 0.75; 95% CI 0.56-1.01; P = 0.06).</p><p><strong>Conclusions: </strong>SGLT2 inhibitors significantly reduced the risk of cardiomyopathy, which further enhances the cardiovascular benefits of SGLT2 inhibitors in clinical settings, especially for patients with heart failure and chronic kidney disease.</p>","PeriodicalId":48802,"journal":{"name":"Journal of Endocrinological Investigation","volume":" ","pages":"2111-2122"},"PeriodicalIF":3.5,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144259202","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessment of first-trimester insulin resistance indices for gestational diabetes mellitus: a prospective cohort study.","authors":"Lirui Zhang, Xin Yan, Wei Zheng, Xianxian Yuan, Ruihua Yang, Junhua Huang, Huiyuan Pang, Yixuan Lu, Yujie Zhang, Tengda Chen, Ziyu Wang, Guanghui Li","doi":"10.1007/s40618-025-02630-4","DOIUrl":"10.1007/s40618-025-02630-4","url":null,"abstract":"<p><strong>Background: </strong>Insulin resistance (IR) is a significant factor in gestational diabetes mellitus (GDM) development. The triglyceride-glucose (TyG) index, triglyceride-glucose body mass index (TyG-BMI), atherogenic index of plasma (AIP), and metabolic score for insulin resistance (METS-IR) are simple and reliable surrogates for assessing IR, but their predictive potential for GDM remains unexplored.</p><p><strong>Methods: </strong>Data from 46,992 singleton pregnancies delivered at Beijing Obstetrics and Gynecology Hospital between 2018 and 2022 were prospectively collected. IR indices were calculated using first-trimester blood lipid and glucose measurements. Participants were classified into GDM and non-GDM groups based on oral glucose tolerance test (OGTT) results at 24-28 weeks. Logistic regression and restricted cubic spline analyses assessed the associations between IR indices and GDM, with subgroup analyses to assess results robustness. The area under the receiver operating characteristic (ROC) curve (AUC) was used to evaluate the predictive performance of the IR indices for GDM.</p><p><strong>Results: </strong>Among the participants, 6,045 were diagnosed with GDM and 40,947 were not. Binary logistic regression showed a significant positive association between first-trimester IR indices and GDM (p < 0.001). AUCs for GDM prediction were 0.646 for TyG, 0.651 for TyG-BMI, 0.629 for AIP, and 0.641 for METS-IR. A basic model with maternal demographics achieved an AUC of 0.666. Adding TyG-BMI improved the AUC to 0.693.</p><p><strong>Conclusions: </strong>All four surrogate IR indices measured in the first trimester were positively associated with GDM, with TyG-BMI emerging as the strongest predictor.</p>","PeriodicalId":48802,"journal":{"name":"Journal of Endocrinological Investigation","volume":" ","pages":"2167-2176"},"PeriodicalIF":3.5,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12398428/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144620855","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Testicular index: clinical, applicable tool to predict pregnancy in men with idiopathic infertility under FSH treatment.","authors":"Daniele Santi, Raffaele Scafa, Giorgia Spaggiari, Giuseppe Grande, Marilina Romeo, Leonardo Dalla Valentina, Andrea Graziani, Antonio Raffaele Michele Granata, Andrea Garolla, Manuela Simoni, Alberto Ferlin","doi":"10.1007/s40618-025-02614-4","DOIUrl":"10.1007/s40618-025-02614-4","url":null,"abstract":"<p><strong>Purpose: </strong>Follicle-stimulating hormone (FSH) therapy improves spermatogenesis, sperm quality, and reproductive outcomes. However, variability in patients' response and limited data on pregnancy rate complicate its extensive application in male idiopathic infertility. The aim of the study was to identify predictors of FSH efficacy in male idiopathic infertility in terms of pregnancy.</p><p><strong>Design: </strong>A retrospective, observational study was conducted at two Italian clinics from 2019 to 2024, enrolling men with idiopathic infertility, serum FSH < 8 IU/L, treated with FSH. Data were collected at baseline (V0) and at the final follow-up visit (V1) when FSH treatment was discontinued. Different, putative \"testicular indexes\" (TI) were calculated. Pregnancy rate was defined at ultrasound confirmation of fetus heartbeat.</p><p><strong>Results: </strong>A total of 84 achieved pregnancy (19%) on 443 patients were recorded. One TI ((FSH + Total testosterone)/bi-testicular volume) was directly related to V0-semen parameters. Significant improvements in sperm concentration (p < 0.001), count (p < 0.001) and motility (p = 0.003) were observed following FSH treatment regardless of pregnancy achievement. Men who achieved pregnancy had lower baseline TI (p = 0.001), larger testicular volume (p = 0.001), and lower FSH concentrations (p = 0.001). Multivariate analysis identified patients' age (B=-0.14, standard error (SE) = 0.05, p = 0.014) and TI (B=-1.51, SE = 0.62, p = 0.015) as significant predictors of pregnancy success.</p><p><strong>Conclusions: </strong>This real-life study identified a novel TI that predicts response to exogenous FSH stimulation. TI assesses the interstitial compartment function (indicated by testosterone concentrations), spermatogenic potential (FSH concentrations), and target tissue amount (testicular volume). Low baseline TI correlates with a higher likelihood of achieving pregnancy through exogenous FSH stimulation.</p>","PeriodicalId":48802,"journal":{"name":"Journal of Endocrinological Investigation","volume":" ","pages":"2187-2196"},"PeriodicalIF":3.5,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144785721","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety of Tocilizumab for thyroid eye disease: a systemic review and Meta-analysis.","authors":"Shuzhen Lin, Xiaodan Ou, Liangchun Cai, Wenxin Huang, Junping Wen","doi":"10.1007/s40618-025-02595-4","DOIUrl":"10.1007/s40618-025-02595-4","url":null,"abstract":"<p><strong>Purpose: </strong>This study aims to investigate efficacy and safety of TCZ in TED.</p><p><strong>Methods: </strong>Performing a meta-analysis of included studies. PubMed, Web of Science, Embase, Cochrane Library, and Clinicatrials.gov databases were retrieved to identify all related published literatures as of May 2024. When I² > 50%, the random effect model was used; otherwise, the fixed model was used.</p><p><strong>Results: </strong>This meta-analysis included 413 patients with TED. Therapeutic effect of TCZ was evaluated by various metrics, including clinical activity score (CAS), response rate, inactivation rate, proptosis, visual acuity (VA), TRAB/TSI levels, diplopia, eye motility, intraocular pressure (IOP), and relapse rate. The final analysis revealed that TCZ significantly reduced CAS (-4.47, 95%CI [-5.14, -3.79]), with high response rate (0.93, 95%CI [0.88, 0.97]) and inactivation rate (0.90, 95%CI [0.83, 0.96]). Significant improvements were also observed in proptosis (2.05 mm reduction, 95%CI [-2.42, -1.67]) and diplopia (0.56 improvement rate, 95% CI [0.40, 0.72]). Regarding safety, the pooled incidence of adverse events (AEs) was 0.31(95%CI [0.15, 0.48]). Hyperlipidemia was the most prevalent AE, followed by neutropenia and infection. Furthermore, subgroup analysis demonstrated TCZ's superior performance in terms of inactivation rate, antibody decline rate, relapse rate, and safety.</p><p><strong>Conclusions: </strong>According to the best available evidence, TCZ appears to be an acceptable alternative for moderate to severe TED patients due to its significant efficacy, well-tolerability, and low relapse rate. Larger sample size and controlled studies are warranted to promote the position of TCZ in TED treatment.</p>","PeriodicalId":48802,"journal":{"name":"Journal of Endocrinological Investigation","volume":" ","pages":"1951-1965"},"PeriodicalIF":3.5,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144021737","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dose-dependent and tissue-specific adverse effects of exogenous glucocorticoids: insights for optimizing clinical practice.","authors":"Riccardo Pofi, Nantia Othonos, Thomas Marjot, Ilaria Bonaventura, Amy Barrett, Sarah White, Hamish Miller, Tom Potter, Maíra Bailey, Richard Eastell, Fatma Gossiel, Conor Woods, Jonathan M Hazlehurst, Leanne Hodson, Jeremy W Tomlinson","doi":"10.1007/s40618-025-02637-x","DOIUrl":"10.1007/s40618-025-02637-x","url":null,"abstract":"<p><strong>Purpose: </strong>There is limited data on dose-specific metabolic effects of exogenous glucocorticoids (GC) doses. This study aimed to investigate the differential tissue-specific and dose-dependent effects of low-to-intermediate prednisolone doses on insulin sensitivity and bone metabolism in healthy individuals.</p><p><strong>Methods: </strong>We performed a post-hoc pooled analysis of three independent clinical trials, each administering one week of daily prednisolone at 10 mg, 15 mg, or 20 mg, in a total of 30 different healthy male volunteers (aged 18-65; BMI 20-35 kg/m²; normal kidney function). Outcome measures included: changes in liver (endogenous glucose production-EGP, β-hydroxybutyrate-OHB), muscle (M/I value, Glucose disposal-Gd) and adipose tissue (NEFA, glycerol) insulin sensitivity assessed across a hyperinsulinemic-euglycemic clamp. Bone turnover was evaluated through osteocalcin levels.</p><p><strong>Results: </strong>Prednisolone 10 mg had minimal impact on metabolic parameters. 15 mg and 20 mg caused similar reductions (no dose effects) in liver (time effect p < 0.05 for EGP and OHB) and skeletal muscle (time effect p < 0.05 for M/I and Gd) insulin sensitivity. However, detrimental effects on adipose tissue were dose dependent (dose*time interaction p < 0.05 for NEFA and glycerol). Osteocalcin levels decreased similarly after both 15 mg and 20 mg of prednisolone (p = 0.199).</p><p><strong>Conclusions: </strong>Prednisolone-induced insulin resistance exhibits tissue-specific and dose-dependent effects. While 15 mg daily for 7 days appears to induce clinically relevant metabolic changes in this population, the dose-dependent effects observed in adipose tissue suggest tissue-specific variability in response. These findings highlight the importance of dose selection in GC therapy, particularly in individuals predisposed to metabolic complications, though further studies are needed in populations with underlying metabolic disorders.</p>","PeriodicalId":48802,"journal":{"name":"Journal of Endocrinological Investigation","volume":" ","pages":"2067-2076"},"PeriodicalIF":3.5,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12398475/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144576736","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sarcopenic obesity and physical function in acromegaly: impact of disease control and evaluation using dual X-ray absorptiometry and multifrequency bioelectrical impedance analysis.","authors":"Arthur Costa Inojosa, Ana Vitória Hirt, Thaís Araújo, Maria Eduarda Ferreira, Luma Andrade, Vinícius Cunha, Daniella Rego, Aline Lopes, Francisco Bandeira","doi":"10.1007/s40618-025-02624-2","DOIUrl":"10.1007/s40618-025-02624-2","url":null,"abstract":"<p><strong>Purpose: </strong>To assess sarcopenia, sarcopenic obesity, physical performance in patients with acromegaly and compare the diagnostic performance of dual-energy X-ray absorptiometry (DXA) and multifrequency bioelectrical impedance analysis (BIA).</p><p><strong>Methods: </strong>This cross-sectional study included 27 patients with acromegaly and 27 age-, sex-, and BMI-matched patients without acromegaly. Body composition was assessed using BIA and DXA. Lean mass indices included fat-free mass index (FFMI) and skeletal muscle index (SMI) via BIA, and the Baumgartner (BMG) and Foundation for the National Institutes of Health indices via DXA. Obesity parameters included fat mass index (FMI) and body fat percentage via BIA. Physical performance was evaluated using handgrip strength (HGS), Timed Up and Go (TUG), 4-m gait speed (4MGS), and the Short Physical Performance Battery (SPPB) tests. The strength, assistance in walking, rising from a chair, climbing stair and falls (SARC-F) questionnaire was also performed.</p><p><strong>Results: </strong>Strong correlations were observed between BIA and DXA body composition measures (r = 0.83, p < 0.01 for %BIA fat mass vs. %DXA fat mass; r = 0.80, p < 0.01 for SMI vs. BMG and r = 0.80, p < 0.01 for FFMI vs. BMG). Patients with acromegaly had significantly higher FFMI than patients without the disease (p = 0.03), but no difference in sarcopenic obesity prevalence (p = 0.50). Patients with acromegaly performed worse in the TUG and 4MGS tests, even after adjustment for confounders (p < 0.01 for both). No significant associations were found between SARC-F scores and lean mass or physical performance.</p><p><strong>Conclusion: </strong>Patients with acromegaly showed impaired physical performance despite higher FFMI, with no differences in sarcopenic obesity. The SARC-F questionnaire showed limited diagnostic value in this population.</p>","PeriodicalId":48802,"journal":{"name":"Journal of Endocrinological Investigation","volume":" ","pages":"2027-2039"},"PeriodicalIF":3.5,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144259203","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Immune checkpoint inhibitors associated thyroiditis: mechanisms and clinical outcomes.","authors":"Sara S Hammerstad, Hanna J Lee, Yaron Tomer, Mihaela Stefan-Lifshitz","doi":"10.1007/s40618-025-02608-2","DOIUrl":"10.1007/s40618-025-02608-2","url":null,"abstract":"<p><p>Background Immune checkpoint inhibitors (ICI) have revolutionized cancer treatment improving prognosis in many cancers. However, ICI often trigger immune-related adverse events (irAEs) that can affect various organ systems, leading to significant clinical challenges. The most frequent irAEs are those affecting the endocrine glands, reported in approximately 10% of treated patients. Thyroid dysfunction is the most common endocrine irAEs, mainly associated with PD-1/PD-L1 blockade therapies. Transient asymptomatic thyrotoxicosis is the most common form of clinical presentation, often followed by hypothyroidism. Interestingly, several studies have demonstrated that irAEs correlate with the response to cancer therapy and with improved overall survival (OS). The mechanisms underlying thyroid irAEs are not fully elucidated but complex interactions between genetic predisposition to thyroid autoimmunity, distinct immune mechanisms and thyroid cell intrinsic mechanisms are thought to drive thyroiditis associated with ICI therapy. Purpose In this review we discuss the latest data on clinical features of thyroid irAEs, proposed mechanisms and their association with improved survival.</p>","PeriodicalId":48802,"journal":{"name":"Journal of Endocrinological Investigation","volume":" ","pages":"2001-2012"},"PeriodicalIF":3.5,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144021739","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring the difference of intra-pancreatic fat distribution in different duration of hyperglycemic patients by MRI multi-point Dixon method and its effect of glucose metabolism status.","authors":"Yingying Song, Kejing Zeng, Bo Chen, Jinwu Liu, Huijuan Xin, Ping Liu, Yao Wang, Gugen Xu, Guihua Jiang","doi":"10.1007/s40618-025-02601-9","DOIUrl":"10.1007/s40618-025-02601-9","url":null,"abstract":"<p><p>This study aimed to quantify intra-pancreatic fat distribution in patients with hyperglycemia using MRI multi-point Dixon method and to investigate the differences of fat distribution in different duration of patients and the effect of glucose metabolism status. Enrolled 189 hyperglycemic patients and divided them into three groups according to disease duration, the newly diagnosed group, and the previously diagnosed group (duration < 5 years, duration ≥ 5 years). Intra-pancreatic fat of patients from head, body, to tail were quantified using the MRI multi-point Dixon method. Compared the differences of regional intra-pancreatic fat distribution among the subgroups. Grouped according to quartiles of fat content in each region of pancreas, then compared the indexes of glucose metabolism status. Intra-pancreatic fat was higher in the previously diagnosed group than in the newly diagnosed group. Intra-pancreatic fat was unevenly distributed, compared them from head, body, and tail of the pancreas existed significant difference (p < 0.0001). Grouped according to quartiles of fat content in the head, body, and tail of the pancreas, in the process of increasing in each region, indexes of islet function were significantly different among the subgroups. In patients with hyperglycemia, intra-pancreatic fat gradually increased with disease duration, and showing a trait of dominantly fat distribution of pancreatic body and tail. Increased each region fat content of pancreas all affected islet function, and increased fat in the tail of pancreas affected the glycemic status of patients.</p>","PeriodicalId":48802,"journal":{"name":"Journal of Endocrinological Investigation","volume":" ","pages":"2137-2149"},"PeriodicalIF":3.5,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144508920","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A CT-based radiomic model for predicting vertebral fractures in older patients with type 2 diabetes mellitus: A longitudinal study.","authors":"Zicheng Wei, Rui Yu, Yiping Zhang, Yu Wang, Jianhua Wang, Cao Xie, Xiao Chen","doi":"10.1007/s40618-025-02627-z","DOIUrl":"10.1007/s40618-025-02627-z","url":null,"abstract":"","PeriodicalId":48802,"journal":{"name":"Journal of Endocrinological Investigation","volume":" ","pages":"2123-2135"},"PeriodicalIF":3.5,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144259201","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}